Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05815485 |
|---|---|
| Brief Title: | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia |
| First Submitted : | April 13, 2023 |
| First Submitted that Met QC Criteria : | April 13, 2023 |
| First Posted : | April 18, 2023 |
| Last Update Submitted that Met QC Criteria : | October 27, 2023 |
| Last Update Posted : | October 31, 2023 |